08:00 , Nov 8, 2010 |  BioCentury  |  Finance

Blue skies for pain plays

Blue skies for pain plays Specialty pharma Pacira Pharmaceuticals Inc. filed to raise up to $86.3 million in an IPO. The company (formerly Blue Acquisition Corp. ) was formed when it acquired the injectable business...
07:00 , Apr 30, 2007 |  BC Week In Review  |  Clinical News

DepoCyt cytarabine regulatory update

FDA granted full approval for DepoCyt cytarabine injection to treat lymphomatous meningitis. DepoCyt received accelerated approval in 2001 (see BioCentury, March 5, 2001). In March, SkyePharma plc (LSE:SKP; SKYE, London, U.K.) sold its injectable business,...
07:00 , Apr 2, 2007 |  BC Week In Review  |  Company News

SkyePharma, Blue Acquisition, Paul Capital Partners deal

SKP completed the previously announced sale of its injectable business, including DepoDur morphine to treat post-surgical pain, to Blue Acquisition for $20 million in cash and up to $62 million in milestones, plus royalties (see...
07:00 , Apr 2, 2007 |  BioCentury  |  Finance

Ebb & Flow

At the beginning of this year, SkyePharma (LSE:SKP; SKYE) laid out three goals it wanted to meet in 2007: complete a restructuring of its royalty financing with Paul Capital, divest its injectable business and complete...
02:09 , Mar 27, 2007 |  BC Extra  |  Company News

SkyePharma sells injectable unit, raises L14.8 million

Drug delivery company SkyePharma (LSE:SKP; SKYE) completed the previously announced sale of its injectable business to Blue Acquisition Corp. for $20 million in cash. SKP is eligible for $62 million in milestones plus sales-related payments....
08:00 , Jan 15, 2007 |  BC Week In Review  |  Company News

SkyePharma, Blue Acquisition deal

SKP agreed to sell its injectable business, SkyePharma Inc., to Blue Acquisition Corp. for $20 million in cash. SKP is eligible for $62 million in milestones, plus royalties. The sale includes marketed products DepoCyt cytarabine...
01:45 , Jan 10, 2007 |  BC Extra  |  Company News

SkyePharma to sell injectable unit, raise L14.8 million

Drug delivery company SkyePharma (LSE:SKP; SKYE) agreed to sell its injectable business to Blue Acquisition Corp. for $20 million in cash. SKP also is eligible for $62 million in milestone payments plus sales-related payments. The...